Within a 60 minute appointment, we offer mobile IV hydration and vitamin therapy right to your home, office, or hotel
Brand-Name Medication Costs (Without Insurance): Semaglutide (Wegovy/Ozempic): List Price: $1,349 per month With Manufacturer Coupon: May reduce to $25/month with commercial insurance (not available for Medicare/Medicaid or cash-pay patients) Average With Insurance: $25-$300 per month depending on coverage Availability: Ongoing shortages affecting access Tirzepatide (Zepbound/Mounjaro): List Price: $1,069 per month With Manufacturer Coupon: May reduce to $25/month with commercial insurance (not available for Medicare/Medicaid or cash-pay patients) Average With Insurance: $25-$300 per month depending on coverage Availability: Better availability than semaglutide, though still limited Compounded Medication Costs: Compounded Semaglutide: TrimRx: $199/month with annual commitment Other Providers: $199-$599/month Insurance: Not covered HSA/FSA: Usually eligible Savings vs Brand-Name: $1,150/month ($13,800/year) Compounded Tirzepatide: TrimRx: $349/month with annual commitment Other Providers: $349-$699/month Insurance: Not covered HSA/FSA: Usually eligible Savings vs Brand-Name: $720/month ($8,640/year) Annual Cost Comparison: Cost vs Effectiveness Analysis: Compounded Options: For the $150/month price difference ($1,800/year) between compounded semaglutide and tirzepatide: You get approximately 7.6% more weight loss on average For a 250-pound person, thats about 19 additional pounds lost Cost per additional pound lost: ~$95 Is the Extra Cost Worth It
Glucagon-like peptide-1 (GLP-1) agonists represent a class of medications that mimic the action of the naturally occurring incretin hormone GLP-1
Most patients experience constipation for 37 days after dose escalation, then improvement as their digestive system adapts
"The last package I received came marked and boxed dog flea treatment, the one before was gone off food
The distinction between direct neuropsychiatric effects and the psychological burden of managing uncomfortable physical side effects is not always clear in clinical practice
